All In Biotech

Drug Trial Radar · NCT04843709

A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

An Open-Label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Actual

Start

Jul 26, 2021

Primary completion

Mar 20, 2024

Study completion Jul 26, 2024

Sponsor

Lead sponsor
Lepu Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic solid tumors.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

  • MRG004ADrug

    Administrated intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)Time frame: DLT will be evaluated during the first treatment cycle (Day 1-21)
  2. Recommended Phase II Dose (RP2D)Time frame: Baseline to study completion (up to 24 months)
  3. Objective Response Rate (ORR)Time frame: Baseline to study completion (up to 24 months)
  4. Adverse Events (AEs)Time frame: From signing informed consent until 45 days after the last dose of MRG004A

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Chao Family Comprehensive Cancer Center

    Orange, California

  • Memorial Sloan Kettering 60th Street Outpatient Center

    New York, New York

  • Gabrail Cancer Center Research

    Canton, Ohio

  • The Christ Hospital Cancer Center

    Cincinnati, Ohio

  • Gettysburg Cancer Center

    Gettysburg, Pennsylvania

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.